Methods of treating developmental encephalopathies
Methods of treating developmental encephalopathies by administering compositions including ketamine, norketamine, or other derivatives of ketamine, or a pharmaceutically acceptable salt of any of the foregoing, are provided. The methods and compositions may be used to treat conditions such as Dravet syndrome.
1. A method of treating Lennox-Gastaut syndrome (LGS) comprising intranasally administering to a patient in need thereof a pharmaceutical composition comprising S-ketamine or a pharmaceutically acceptable salt thereof in an amount ranging from about 1 mg to about 100 mg.
2. The method of claim 1 wherein the S-ketamine or the pharmaceutically acceptable salt thereof is administered at a dosage selected from the group consisting of about 10 mg, 20 mg, 28 mg, 40 mg, 56 mg, 80 mg and 84 mg.
3. The method of claim 2 wherein the S-ketamine or the pharmaceutically acceptable salt thereof is administered at a dosage of about 28 mg.
4. The method of claim 1 wherein the pharmaceutically acceptable salt thereof is an acid addition salt.
5. The method of claim 4 wherein the acid addition salt is S-ketamine hydrochloride.
6. The method of claim 5 wherein the S-ketamine hydrochloride is administered at a dosage of about 32.3 mg.
7. The method of claim 1 , wherein administration of the composition comprising S-ketamine or the pharmaceutically acceptable salt thereof provides an in vivo plasma profile comprising a C max less than about 38 ng/ml.
8. The method of claim 1 wherein the S-ketamine or the pharmaceutically acceptable salt thereof is administered once daily.
9. The method of claim 1 wherein the S-ketamine or the pharmaceutically acceptable salt thereof is administered once weekly.
10. The method of claim 1 wherein the S-ketamine or the pharmaceutically acceptable salt thereof is administered twice weekly.
11. The method of claim 1 wherein the amount of the S-ketamine or the pharmaceutically acceptable salt thereof is administered in an amount ranging from about 0.1 mg/kg and about 10 mg/kg of body weight of the patient.
12. The method of claim 1 , wherein administration of the composition comprising S-ketamine or the pharmaceutically acceptable salt thereof provides an in vivo plasma profile comprising an AUC 0-∞ less than about 200 ng·hr/ml.